ArticleClinical rheumatology2026
Therapeutic effects of hUC-MSCs on collagen-induced arthritis are associated with immune rebalancing and systemic metabolic changes.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundRheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Although current therapies can control symptoms, many patients still have limited responses or safety concerns. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have shown therapeutic potential in autoimmune diseases, but their effects on joint-associated pathways and systemic metabolism in RA remain unclear.
methodshUC-MSCs were commercially obtained, expanded, and characterized. A collagen-induced arthritis (CIA) mouse model was established to evaluate therapeutic efficacy. Disease severity was assessed by arthritis scoring, gross observation, and histopathology. Flow cytometry and ELISA were used to analyze Th17/Treg balance and circulating cytokines. NF-κB- and Wnt/β-catenin-related molecules, together with components of the RANKL/OPG axis, were examined by Western blotting and RT-qPCR. Untargeted plasma metabolomics was performed to assess systemic metabolic changes.
resultshUC-MSC treatment reduced arthritis scores and joint swelling in CIA mice. Histological analysis showed reduced synovial hyperplasia and less cartilage and bone damage. hUC-MSCs shifted the immune profile toward an anti-inflammatory state, with decreased Th17 cells, increased Treg cells, and lower serum TNF-α, IL-6, IL-1β, and IL-17 levels. In synovial tissue, hUC-MSC treatment was associated with lower expression of NF-κB p65, Wnt-4, and β-catenin, as well as a decreased RANKL/OPG ratio. Exploratory untargeted metabolomics further suggested treatment-associated changes in the systemic metabolic profile.
conclusionhUC-MSCs alleviated arthritis in CIA mice and were associated with immune rebalancing, lower expression of inflammation-related molecular markers, and systemic metabolic changes. Key Points • hUC-MSCs attenuate synovitis and bone destruction in CIA mice. • hUC-MSC treatment restores Th17/Treg balance and is associated with lower expression of NF-κB/Wnt-related markers. • Untargeted metabolomics suggests treatment-associated systemic metabolic changes.
Indexed as
Identifiers
42709300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.